review · Pharmaceuticals
Bacterial pathogens increasingly evade standard treatments through diverse resistance mechanisms, including reduced membrane permeability, target site modifications, biofilm formation, enzymatic drug degradation, and active efflux systems such as ABC, RND, MFS, MATE, SMR, and PACE transporters. To address this crisis, several alternative therapeutic interventions are under investigation. These include biological approaches such as bacteriophages, antimicrobial peptides, probiotics, postbiotics, synbiotics, stem cells, and immunotherapy. Other innovative strategies involve quorum quenching, antibacterial photodynamic therapy, animal-venom-derived molecules, and nanobiotics. Additionally, CRISPR-Cas systems provide opportunities for targeted genetic interventions against resistant strains. Advancing these novel antibacterial strategies requires sustained, cross-disciplinary collaboration between biomedical researchers and the pharmaceutical industry to establish effective alternatives to traditional antibiotics and counter the threat of multidrug-resistant infections.
The global spread of multidrug-resistant bacteria threatens modern healthcare by rendering conventional antibiotics ineffective against common infections. Examining how bacteria evade drugs and identifying non-traditional therapies, from bacteriophages to gene-editing tools, helps guide future treatments. Sustained efforts to develop alternative antimicrobial agents are vital for safeguarding public health and preserving the ability to control life-threatening bacterial diseases worldwide.
This work outlines candidate solutions for pharmaceutical companies and biotechnology developers seeking alternatives to failing antibiotics. Highlighted modalities, such as animal-venom compounds, nanobiotics, antimicrobial peptides, and CRISPR-based tools, point towards prospective new therapeutic pipelines. While these approaches represent diverse opportunities for commercial drug discovery, the focus on synthesising research advancements places them largely in the early-stage to exploratory phase of development.
AI-generated from the published abstract. Always read the original work before citing.
The escalating global health crisis of antibiotic resistance, driven by the rapid emergence of multidrug-resistant (MDR) bacterial pathogens, necessitates urgent and innovative countermeasures. This review comprehensively examines the diverse mechanisms employed by bacteria to evade antibiotic action, including alterations in cell membrane permeability, efflux pump overexpression, biofilm formation, target site modifications, and the enzymatic degradation of antibiotics. Specific focus is given to membrane transport systems such as ATP-binding cassette (ABC) transporters, resistance-nodulation-division (RND) efflux pumps, major facilitator superfamily (MFS) transporters, multidrug and toxic compound extrusion (MATE) systems, small multidrug resistance (SMR) families, and proteobacterial antimicrobial compound efflux (PACE) families. Additionally, the review explores the global burden of MDR pathogens and evaluates emerging therapeutic strategies, including quorum quenching (QQ), probiotics, postbiotics, synbiotics, antimicrobial peptides (AMPs), stem cell applications, immunotherapy, antibacterial photodynamic therapy (aPDT), and bacteriophage. Furthermore, this review discusses novel antimicrobial agents, such as animal-venom-derived compounds and nanobiotics, as promising alternatives to conventional antibiotics. The interplay between clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) in bacterial adaptive immunity is analyzed, revealing opportunities for targeted genetic interventions. By synthesizing current advancements and emerging strategies, this review underscores the necessity of interdisciplinary collaboration among biomedical scientists, researchers, and the pharmaceutical industry to drive the development of novel antibacterial agents. Ultimately, this comprehensive analysis provides a roadmap for future research, emphasizing the urgent need for sustainable and cooperative approaches to combat antibiotic resistance and safeguard global health.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/ph18030402
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
